ANA Investigates: Neurological Complications of COVID-19 Vaccines
Corresponding Author
Adeline L. Goss MD
Department of Neurology, University of California San Francisco, San Francisco, CA
Address correspondence to Adeline L. Goss, MD, Neurohospitalist Fellow, Department of Neurology, University of California San Francisco, 505 Parnassus Avenue, Box 0114, San Francisco, CA 94143. E-mail: [email protected]
Search for more papers by this authorRohini D. Samudralwar MD
Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX
Search for more papers by this authorRohit R. Das MD, MPH
Department of Neurology, UT Southwestern Medical Center, Dallas, TX
Search for more papers by this authorAvindra Nath MD
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD
Search for more papers by this authorCorresponding Author
Adeline L. Goss MD
Department of Neurology, University of California San Francisco, San Francisco, CA
Address correspondence to Adeline L. Goss, MD, Neurohospitalist Fellow, Department of Neurology, University of California San Francisco, 505 Parnassus Avenue, Box 0114, San Francisco, CA 94143. E-mail: [email protected]
Search for more papers by this authorRohini D. Samudralwar MD
Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX
Search for more papers by this authorRohit R. Das MD, MPH
Department of Neurology, UT Southwestern Medical Center, Dallas, TX
Search for more papers by this authorAvindra Nath MD
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD
Search for more papers by this authorPotential Conflicts of Interest
The authors declared no conflict of interest.
References
- 1Allen A, Szabo L, Kaiser Health News. NIH “Very Concerned” about Serious Side Effect in Coronavirus Vaccine Trial [Internet]. Scientific American 2020. Available at: https://www.scientificamerican.com/article/nih-very-concerned-about-serious-side-effect-in-coronavirus-vaccine-trial/. Accessed February 27, 2021.
- 2Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111.
- 3Ledford H. US authorization of first COVID vaccine marks new phase in safety monitoring. Nature 2020; 588: 377–378.
- 4 CDC. COVID-19 Vaccination Considerations for Persons with Underlying Medica [Internet]. Centers for Disease Control and Prevention 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/underlying-conditions.html. Accessed March 11, 2021.
- 5Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. [date unknown];24.
- 6Gee J. First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 [Internet]. MMWR Morb Mortal Wkly Rep 2021;70. Available at: https://www.cdc.gov/mmwr/volumes/70/wr/mm7008e3.htm. Accessed March 10, 2021
- 7 IDSA COVID-19 Real Time Learning Network Editorial Staff. COVID-19 Real-Time Learning Network: Vaccines FAQ [Internet]. 2021. Available at: https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/vaccines-information-faq/. Accessed February 27, 2021
- 8Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord 2020; 45:102439.
- 9 Timing MS Medications with COVID-19 mRNA Vaccines [Internet]. National Multiple Sclerosis Society [date unknown]. Available at: https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-mRNA-Vaccines. Accessed February 27, 2021
- 10 Foundation Global Medical Advisory Board statement on COVID vaccines for CIDP and MMN [Internet]. GBS/CIDP Foundation International 2021. Available at: https://www.gbs-cidp.org/2021/01/21/foundation-global-medical-advisory-board-statement-on-covid-vaccines-for-cidp-and-mmn/. Accessed February 27, 2021
Citing Literature
